REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID.

Front Neurosci · 2025 · PMC12313680 · PMID 40757370

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the primary outcome, fatigue reduction measured by the CFQ, did not reach statistical significance, the pattern of the results across the secondary and exploratory measures suggests potential clinical benefits of OAA for this population.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.